Qiagen N.V. (QGEN): Capital Expenditures
$201.05M
Year ended 2025-12-31
+15.9%
3-year compound annual growth
+8.6%
5-year compound annual growth
+7.5%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $201.05M | +20.3% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $167.17M | +11.7% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $149.71M | +15.9% | 2026-03-20, From 2023-01-01 |
| 2022-12-31 | $129.22M | -32.0% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $189.90M | +43.0% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $132.79M | +12.6% | 2023-03-13, From 2020-01-01 |
| 2019-12-31 | $117.95M | +7.4% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $109.77M | +21.9% | 2021-03-05, From 2018-01-01 |
| 2017-12-31 | $90.08M | +20.9% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $74.54M | -23.8% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $97.78M | +12.9% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $86.59M | +2.5% | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | $84.47M | -17.2% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $102.00M | +17.5% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $86.81M | +9.0% | 2014-03-03, From 2011-01-01 |
| 2010-12-31 | $79.67M | +52.7% | 2013-03-04, From 2010-01-01 |
| 2009-12-31 | $52.18M | +32.3% | 2012-03-27, From 2009-01-01 |
| 2008-12-31 | $39.45M | n/a | 2011-03-21, From 2008-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Qiagen N.V. (QGEN) | 2025-12-31 | $201.05M | +20.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $192.00M | -81.7% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $8.43M | -70.4% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $34.00M | -11.0% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $6.97M | -34.8% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $2.47M | +119.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $22.57M | +174.4% |
Compare QGEN, MRNA, EXEL, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗